Survivors of Hodgkin's lymphoma (HL) frequently have many years to experience the long‐
term toxicities of combined modality therapies. Also, a significant proportion of HL patients …

Hodgkin's lymphomas belong to the most curable tumor diseases in adults. About 80% of
patients in all anatomical stages and of all histological subtypes can be cured with modern …

Background High-dose chemotherapy followed by transplantation of autologous
haemopoietic stem cells (BEAMHSCT) is frequently used to treat patients with relapsed …

Abstract The European Group for Blood and Marrow Transplantation regularly publishes
special reports on the current practice of haematopoietic SCT for haematological diseases …

Purpose To compare the clinical outcome in terms of nonrelapse mortality (NRM), relapse
rate (RR), overall survival (OS), and progression-free survival (PFS) in patients with relapsed …

Background Although Hodgkin's lymphoma is a highly curable disease with modern
chemotherapy protocols, some patients are primary refractory or relapse after first-line …

Background In patients with multiply relapsed Hodgkin's lymphoma allogeneic stem-cell
transplantation has been limited by prohibitive non-relapse-related mortality rates and by a …

Relapsed or refractory Hodgkin lymphoma is a challenging problem for clinicians who treat
hematologic malignancies. The standard management of these patients should include the …

Data on the application of donor lymphocyte infusions (DLIs) following reduced-intensity
transplantation (RIT) remain limited. Persistence of host antigen-presenting cells might …

Background The role of reduced intensity conditioning allogeneic stem transplantation
(RICalloSCT) in the management of patients with Hodgkin's lymphoma remains …